Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC11A2: a promising biomarker and therapeutic target in ovarian cancer

20 Jan 2023

Abstract excerpt

Ovarian cancer has the highest mortality rate among gynecologic tumors, with a 5-year survival rate of less than 25%. There is an urgent need for early diagnosis and new drugs to reduce the disease burden of ovarian cancer. The aim of this study was to investigate the effectiveness of SLC11A2 as a therapeutic target and marker for ovarian cancer. Expression data of SLC11A2 were obtained from public databases....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36670142
DOI: 10.1038/s41598-022-26789-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC11A2: a promising biomarker and therapeutic target in ovarian cancerPMID 36670142Read ↗

SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.Semantic proximity Read ↗

Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases.Semantic proximity Read ↗

Epithelial Ovarian Cancer: Disease Etiology, Treatment, Detection, and Investigational Gene, Metabolite, and Protein BiomarkersSemantic proximity Read ↗

Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous CystadenocarcinomaSemantic proximity Read ↗

Comprehensive analyses of solute carrier family members identify SLC12A2 as a novel therapy target for colorectal cancer.Semantic proximity Read ↗

An overview of biomarkers for the ovarian cancer diagnosis.Semantic proximity Read ↗

An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancerSemantic proximity Read ↗

Comprehensive Analysis and Validation of Solute Carrier Family 25 (SLC25) in Pan-CancerSemantic proximity Read ↗

Applications of Proteomics in Ovarian Cancer: Dawn of a New EraSemantic proximity Read ↗

SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancerSemantic proximity Read ↗

SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNASemantic proximity Read ↗

The circulating miRNA-34a, miRNA -143 and miRNA -212 are promising biomarkers in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.